WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
New art space integrates art with technologyChinese books attract global attention at Italy's biggest book fairNorthern Ireland secretary Chris HeatonYoung people work to preserve precious pastElon Musk arrives in Indonesia's Bali to launch Starlink satellite internet serviceIsrael announces reopening of Kerem Shalom crossing with GazaChinese foreign minister holds talks with ROK counterpartNadhim Zahawi insists Tories were 'wrong to oust Boris Johnson': Former Chancellor hails exSeth Lugo claims ALVisitors flock to celebrate Hong Kong's unique Bun Festival
1.9701s , 6503.0703125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Glance news portal